Physical Medicine and Rehabilitation Clinics of North America 2012-11-01

Novel approaches to corticosteroid treatment in Duchenne muscular dystrophy.

Eric P Hoffman, Erica Reeves, Jesse Damsker, Kanneboyina Nagaraju, John M McCall, Edward M Connor, Kate Bushby

Index: Phys. Med. Rehabil. Clin. N. Am. 23(4) , 821-8, (2012)

Full Text: HTML

Abstract

Although prednisone has never been formally approved for use in Duchenne muscular dystrophy (DMD) by regulatory agencies, its efficacy has been confirmed in trials dating from the 1980s. There is a strong need for optimization of both specific type of glucocorticoid (eg, prednisone, vs deflazacort or others) and the dosing regimen. Ideally an optimized regimen would maximize efficacy while minimizing side-effect profiles. A new trial, FOR-DMD, aims to address this gap in knowledge. In parallel, there has been progress in the area of "dissociative steroids," drugs that are able to better separate efficacy and side effects, providing a broader therapeutic window.Copyright © 2012 Elsevier Inc. All rights reserved.

Related Compounds

  • Deflazacort

Related Articles:

Health-related quality of life in children and adolescents with Duchenne muscular dystrophy.

2012-12-01

[Pediatrics 130(6) , e1559-66, (2012)]

Early corticosteroid treatment in 4 Duchenne muscular dystrophy patients: 14-year follow-up.

2012-06-01

[Muscle Nerve 45(6) , 796-802, (2012)]

Treatment of dysferlinopathy with deflazacort: a double-blind, placebo-controlled clinical trial.

2013-01-01

[Orphanet J. Rare Dis. 8 , 26, (2013)]

Acute and chronic corticosteroid treatment of ten patients with paralytic form of Sydenham's chorea.

2012-07-01

[Eur. J. Paediatr. Neurol. 16(4) , 373-8, (2012)]

Oral pemphigus: long term behaviour and clinical response to treatment with deflazacort in sixteen cases.

2000-04-01

[J. Oral. Pathol. Med. 29(4) , 145-52, (2000)]

More Articles...